Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/1b Study of AMG 436 in MSI-H/dMMR Solid Tumors
jRCT2031250764Phase 1Recruiting
- Sponsor
- Amgen
- Start
- Apr 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of AMG 436 in Nonhematologic neoplasms and Metastatic solid neoplasm (5 arms), sponsored by Amgen. Primary endpoints: Dose Limiting Toxicity (DLT) and Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs). Started Apr 2026; status: recruiting.
02
Drugs
AMG 436
03
Conditions
Nonhematologic neoplasmsMetastatic solid neoplasm
Beyond the preview
Go deeper on jRCT2031250764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250764.